Pan-Canadian review of cancer drugs will not be binding on provinces

In a bid to encourage a more consistent standard of therapy across Canada, a national oncology drug review process will be launched this fall to provide all provinces except Quebec with common recommendations on the clinical and cost-effectiveness of new cancer drugs. But patient advocacy groups